结核病疫苗
医学
肺结核
病毒学
结核分枝杆菌
dna疫苗
减毒疫苗
临床试验
牛分枝杆菌
接种疫苗
免疫学
免疫
生物
免疫系统
毒力
生物化学
病理
基因
作者
Zhuang Li,Zhaoyang Ye,Linsheng Li,Yang Liu,Wenping Gong
出处
期刊:Vaccines
[MDPI AG]
日期:2023-07-31
卷期号:11 (8): 1304-1304
被引量:12
标识
DOI:10.3390/vaccines11081304
摘要
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a prevalent global infectious disease and a leading cause of mortality worldwide. Currently, the only available vaccine for TB prevention is Bacillus Calmette–Guérin (BCG). However, BCG demonstrates limited efficacy, particularly in adults. Efforts to develop effective TB vaccines have been ongoing for nearly a century. In this review, we have examined the current obstacles in TB vaccine research and emphasized the significance of understanding the interaction mechanism between MTB and hosts in order to provide new avenues for research and establish a solid foundation for the development of novel vaccines. We have also assessed various TB vaccine candidates, including inactivated vaccines, attenuated live vaccines, subunit vaccines, viral vector vaccines, DNA vaccines, and the emerging mRNA vaccines as well as virus-like particle (VLP)-based vaccines, which are currently in preclinical stages or clinical trials. Furthermore, we have discussed the challenges and opportunities associated with developing different types of TB vaccines and outlined future directions for TB vaccine research, aiming to expedite the development of effective vaccines. This comprehensive review offers a summary of the progress made in the field of novel TB vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI